Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Change in Account Payables of $3.1 million for Q1 2026, up 435.47% year-over-year from $578000.0 in Q1 2025, and down 31.18% quarter-over-quarter from $4.5 million in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Change in Account Payables for 11 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 435.47% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $8.1 million (up 141.46% YoY), while the FY2025 annual figure was $5.5 million, up 83.48% from the prior year.
- Change in Account Payables eased to $3.1 million in Q1 2026 per FBRX's latest filing, from $4.5 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.5 million in Q4 2025 and bottomed at -$3.9 million in Q4 2023.
- Historically, Change in Account Payables has averaged $713941.2 across 5 years, with a median of $261000.0 in 2024.
- On a YoY basis, Change in Account Payables climbed as much as 1689.25% in 2023 and fell as far as 21577.78% in 2023.
- Forte Biosciences' Change in Account Payables stood at $18000.0 in 2022, then sank by 21577.78% to -$3.9 million in 2023, then jumped by 81.53% to -$714000.0 in 2024, then soared by 729.83% to $4.5 million in 2025, then tumbled by 31.18% to $3.1 million in 2026.
- Business Quant data shows FBRX's Change in Account Payables at $3.1 million in Q1 2026, $4.5 million in Q4 2025, and $558000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | 388,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 388,000.00 |
| Mar 31, 2026 | 3.10 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 558,000.00 |
| Jun 30, 2025 | -90,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 261,000.00 |
| Dec 31, 2023 | -3.87 Mn |
| Sep 30, 2023 | 2.28 Mn |
| Jun 30, 2023 | 1.66 Mn |
| Mar 31, 2023 | 189,000.00 |
| Dec 31, 2022 | 18,000.00 |
| Sep 30, 2022 | 466,000.00 |
| Jun 30, 2022 | 93,000.00 |
| Mar 31, 2022 | -370,000.00 |
| Dec 31, 2021 | -1.38 Mn |
| Sep 30, 2021 | 1.35 Mn |